These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33868363)

  • 21. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology.
    Van Sciver RE; Lee MP; Lee CD; Lafever AC; Svyatova E; Kanda K; Colliver AL; Siewertsz van Reesema LL; Tang-Tan AM; Zheleva V; Bwayi MN; Bian M; Schmidt RL; Matrisian LM; Petersen GM; Tang AH
    Cancers (Basel); 2018 May; 10(5):. PubMed ID: 29757973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents.
    Yang Y; Vankayalapati H; Tang M; Zheng Y; Li Y; Ma C; Lai K
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32028604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical data mining by fuzzy modeling with selected features.
    Ghazavi SN; Liao TW
    Artif Intell Med; 2008 Jul; 43(3):195-206. PubMed ID: 18534831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
    Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
    Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mathematical modeling for novel cancer drug discovery and development.
    Zhang P; Brusic V
    Expert Opin Drug Discov; 2014 Oct; 9(10):1133-50. PubMed ID: 25062617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy in combating cancer.
    Bayat Mokhtari R; Homayouni TS; Baluch N; Morgatskaya E; Kumar S; Das B; Yeger H
    Oncotarget; 2017 Jun; 8(23):38022-38043. PubMed ID: 28410237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Efficacious Multi-Objective Fuzzy Linear Programming Approach for Optimal Power Flow Considering Distributed Generation.
    Warid W; Hizam H; Mariun N; Abdul-Wahab NI
    PLoS One; 2016; 11(3):e0149589. PubMed ID: 26954783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computationally efficient approach for identification of fuzzy dynamic groundwater sampling network.
    Kumari K; Jain S; Dhar A
    Environ Monit Assess; 2019 Apr; 191(5):310. PubMed ID: 31030264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
    Blum R; Kloog Y
    Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes.
    Regan-Fendt KE; Xu J; DiVincenzo M; Duggan MC; Shakya R; Na R; Carson WE; Payne PRO; Li F
    NPJ Syst Biol Appl; 2019; 5():6. PubMed ID: 30820351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization and Modeling of Process Parameters in Multi-Hole Simultaneous Drilling Using Taguchi Method and Fuzzy Logic Approach.
    Aamir M; Tu S; Tolouei-Rad M; Giasin K; Vafadar A
    Materials (Basel); 2020 Feb; 13(3):. PubMed ID: 32028691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer.
    Wang Q; Wang Z; Wu Y; Klinke DJ
    BMC Cancer; 2020 Jan; 20(1):26. PubMed ID: 31914948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells.
    El-Mashtoly SF; Yosef HK; Petersen D; Mavarani L; Maghnouj A; Hahn S; Kötting C; Gerwert K
    Anal Chem; 2015 Jul; 87(14):7297-304. PubMed ID: 26075314
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Bora N; Jha AN
    Front Genet; 2020; 11():179. PubMed ID: 32211028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.
    Xiao Z; Mak A; Koch K; Moore RB
    BJU Int; 2013 Jul; 112(2):E201-10. PubMed ID: 23356235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-scale computational study of the Warburg effect, reverse Warburg effect and glutamine addiction in solid tumors.
    Shan M; Dai D; Vudem A; Varner JD; Stroock AD
    PLoS Comput Biol; 2018 Dec; 14(12):e1006584. PubMed ID: 30532226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic neuro-fuzzy modeling framework with application to material property prediction.
    Chen MY; Linkens DA
    IEEE Trans Syst Man Cybern B Cybern; 2001; 31(5):781-90. PubMed ID: 18244842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.